BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 16446975)

  • 1. Genetic alterations in caspase-10 may be causative or protective in autoimmune lymphoproliferative syndrome.
    Zhu S; Hsu AP; Vacek MM; Zheng L; Schäffer AA; Dale JK; Davis J; Fischer RE; Straus SE; Boruchov D; Saulsbury FT; Lenardo MJ; Puck JM
    Hum Genet; 2006 Apr; 119(3):284-94. PubMed ID: 16446975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the potential role of CASPASE-10 mutations in the development of autoimmune lymphoproliferative syndrome.
    Consonni F; Moreno S; Vinuales Colell B; Stolzenberg MC; Fernandes A; Parisot M; Masson C; Neveux N; Rosain J; Bamberger S; Vigue MG; Malphettes M; Quartier P; Picard C; Rieux-Laucat F; Magerus A
    Cell Death Dis; 2024 May; 15(5):315. PubMed ID: 38704374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoimmune lymphoproliferative syndrome due to somatic FAS mutation (ALPS-sFAS) combined with a germline caspase-10 (CASP10) variation.
    Martínez-Feito A; Melero J; Mora-Díaz S; Rodríguez-Vigil C; Elduayen R; González-Granado LI; Pérez-Méndez D; Sánchez-Zapardiel E; Ruiz-García R; Menchén M; Díaz-Madroñero J; Paz-Artal E; Del Orbe-Barreto R; Riñón M; Allende LM
    Immunobiology; 2016 Jan; 221(1):40-7. PubMed ID: 26323380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-inherited mutations of Fas and caspase-10 in development of the autoimmune lymphoproliferative syndrome.
    Cerutti E; Campagnoli MF; Ferretti M; Garelli E; Crescenzio N; Rosolen A; Chiocchetti A; Lenardo MJ; Ramenghi U; Dianzani U
    BMC Immunol; 2007 Nov; 8():28. PubMed ID: 17999750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FAS-mediated apoptosis impairment in patients with ALPS/ALPS-like phenotype carrying variants on CASP10 gene.
    Miano M; Cappelli E; Pezzulla A; Venè R; Grossi A; Terranova P; Palmisani E; Maggiore R; Guardo D; Lanza T; Calvillo M; Micalizzi C; Pierri F; Vernarecci C; Beccaria A; Corsolini F; Lanciotti M; Russo G; Ceccherini I; Dufour C; Fioredda F
    Br J Haematol; 2019 Nov; 187(4):502-508. PubMed ID: 31309545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALPS: an autoimmune human lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis.
    Puck JM; Sneller MC
    Semin Immunol; 1997 Feb; 9(1):77-84. PubMed ID: 9106310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoimmune lymphoproliferative syndrome, a disorder of apoptosis.
    Jackson CE; Puck JM
    Curr Opin Pediatr; 1999 Dec; 11(6):521-7. PubMed ID: 10590910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis.
    Sneller MC; Wang J; Dale JK; Strober W; Middelton LA; Choi Y; Fleisher TA; Lim MS; Jaffe ES; Puck JM; Lenardo MJ; Straus SE
    Blood; 1997 Feb; 89(4):1341-8. PubMed ID: 9028957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoimmune lymphoproliferative syndrome type III: an indefinite disorder.
    Van Der Werff Ten Bosch J; Otten J; Thielemans K
    Leuk Lymphoma; 2001 Mar; 41(1-2):55-65. PubMed ID: 11342357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance.
    Jackson CE; Fischer RE; Hsu AP; Anderson SM; Choi Y; Wang J; Dale JK; Fleisher TA; Middelton LA; Sneller MC; Lenardo MJ; Straus SE; Puck JM
    Am J Hum Genet; 1999 Apr; 64(4):1002-14. PubMed ID: 10090885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dominant inhibition of Fas ligand-mediated apoptosis due to a heterozygous mutation associated with autoimmune lymphoproliferative syndrome (ALPS) Type Ib.
    Bi LL; Pan G; Atkinson TP; Zheng L; Dale JK; Makris C; Reddy V; McDonald JM; Siegel RM; Puck JM; Lenardo MJ; Straus SE
    BMC Med Genet; 2007 Jul; 8():41. PubMed ID: 17605793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunophenotypic profiles in families with autoimmune lymphoproliferative syndrome.
    Bleesing JJ; Brown MR; Straus SE; Dale JK; Siegel RM; Johnson M; Lenardo MJ; Puck JM; Fleisher TA
    Blood; 2001 Oct; 98(8):2466-73. PubMed ID: 11588044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inherited and acquired death receptor defects in human Autoimmune Lymphoproliferative Syndrome.
    Rieux-Laucat F
    Curr Dir Autoimmun; 2006; 9():18-36. PubMed ID: 16394653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristic T helper 2 T cell cytokine abnormalities in autoimmune lymphoproliferative syndrome, a syndrome marked by defective apoptosis and humoral autoimmunity.
    Fuss IJ; Strober W; Dale JK; Fritz S; Pearlstein GR; Puck JM; Lenardo MJ; Straus SE
    J Immunol; 1997 Feb; 158(4):1912-8. PubMed ID: 9029133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA B44 is associated with decreased severity of autoimmune lymphoproliferative syndrome in patients with CD95 defects (ALPS type Ia).
    Vacek MM; Schäffer AA; Davis J; Fischer RE; Dale JK; Adams S; Straus SE; Puck JM
    Clin Immunol; 2006 Jan; 118(1):59-65. PubMed ID: 16257267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased activation-induced cell death by EBV-transformed B-cells from a patient with autoimmune lymphoproliferative syndrome caused by a novel FASLG mutation.
    Ruiz-García R; Mora S; Lozano-Sánchez G; Martínez-Lostao L; Paz-Artal E; Ruiz-Contreras J; Anel A; González-Granado LI; Moreno-Pérez D; Allende LM
    Pediatr Res; 2015 Dec; 78(6):603-8. PubMed ID: 26334989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression in transgenic mice of dominant interfering Fas mutations: a model for human autoimmune lymphoproliferative syndrome.
    Choi Y; Ramnath VR; Eaton AS; Chen A; Simon-Stoos KL; Kleiner DE; Erikson J; Puck JM
    Clin Immunol; 1999 Oct; 93(1):34-45. PubMed ID: 10497009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II.
    Wang J; Zheng L; Lobito A; Chan FK; Dale J; Sneller M; Yao X; Puck JM; Straus SE; Lenardo MJ
    Cell; 1999 Jul; 98(1):47-58. PubMed ID: 10412980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS).
    Teachey DT; Manno CS; Axsom KM; Andrews T; Choi JK; Greenbaum BH; McMann JM; Sullivan KE; Travis SF; Grupp SA
    Blood; 2005 Mar; 105(6):2443-8. PubMed ID: 15542578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical, immunological, and genetic features in 780 patients with autoimmune lymphoproliferative syndrome (ALPS) and ALPS-like diseases: A systematic review.
    Hafezi N; Zaki-Dizaji M; Nirouei M; Asadi G; Sharifinejad N; Jamee M; Erfan Rasouli S; Hamedifar H; Sabzevari A; Chavoshzadeh Z; Yazdani R; Abolhassani H; Aghamohammadi A; Azizi G
    Pediatr Allergy Immunol; 2021 Oct; 32(7):1519-1532. PubMed ID: 33963613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.